Literature DB >> 16971504

The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors.

Piotr Popik1, Emmanuel Kostakis, Martyna Krawczyk, Gabriel Nowak, Bernadeta Szewczyk, Philip Krieter, Zhengming Chen, Shelley J Russek, Terrell T Gibbs, David H Farb, Phil Skolnick, Arnold S Lippa, Anthony S Basile.   

Abstract

Studies using mice with point mutations of GABA(A) receptor alpha subunits suggest that the sedative and anxiolytic properties of 1,4-benzodiazepines are mediated, respectively, by GABA(A) receptors bearing the alpha(1) and alpha(2) subunits. This hypothesis predicts that a compound with high efficacy at GABA(A) receptors containing the alpha(1) subunit would produce sedation, whereas an agonist acting at alpha(2) subunit-containing receptors (with low or null efficacy at alpha(1)-containing receptors) would be anxioselective. Electrophysiological studies using recombinant GABA(A) receptors expressed in Xenopus oocytes indicate that maximal potentiation of GABA-stimulated currents by the pyrazolo-[1,5-a]-pyrimidine, DOV 51892, at alpha(1)beta(2)gamma(2S) constructs of the GABA(A) receptor was significantly higher (148%) than diazepam. In contrast, DOV 51892 was considerably less efficacious and/or potent than diazepam in enhancing GABA-stimulated currents mediated by constructs containing alpha(2), alpha(3), or alpha(5) subunits. In vivo, DOV 51892 increased punished responding in the Vogel conflict test, an effect blocked by flumazenil, and increased the percentage of time spent in the open arms of the elevated plus-maze. However, DOV 51892 had no consistent effects on motor function or muscle relaxation at doses more than 1 order of magnitude greater than the minimal effective anxiolytic dose. Although the mutant mouse data predict that the high-efficacy potentiation of GABA(A1a) receptor-mediated currents by DOV 51892 would be sedating, behavioral studies demonstrate that DOV 51892 is anxioselective, indicating that GABA potentiation mediated by alpha(1) subunit-containing GABA(A) receptors may be neither the sole mechanism nor highly predictive of the sedative properties of benzodiazepine recognition site modulators.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971504     DOI: 10.1124/jpet.106.107201

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  A novel protocol for catalyst-free synthesis of fused six-member rings to triazole and pyrazole.

Authors:  Sedigheh Akrami; Bahador Karami; Mahnaz Farahi
Journal:  Mol Divers       Date:  2019-04-01       Impact factor: 2.943

2.  Lack of persistent effects of ketamine in rodent models of depression.

Authors:  Piotr Popik; Tomasz Kos; Magdalena Sowa-Kućma; Gabriel Nowak
Journal:  Psychopharmacology (Berl)       Date:  2008-05-07       Impact factor: 4.530

3.  The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration.

Authors:  Agnieszka Nikiforuk; Tomasz Kos; Anna Wesołowska
Journal:  Psychopharmacology (Berl)       Date:  2011-04-16       Impact factor: 4.530

Review 4.  Structure, function, and modulation of GABA(A) receptors.

Authors:  Erwin Sigel; Michael E Steinmann
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

5.  Altered cortical GABAA receptor composition, physiology, and endocytosis in a mouse model of a human genetic absence epilepsy syndrome.

Authors:  Chengwen Zhou; Zhiling Huang; Li Ding; M Elizabeth Deel; Fazal M Arain; Clark R Murray; Ronak S Patel; Christopher D Flanagan; Martin J Gallagher
Journal:  J Biol Chem       Date:  2013-06-06       Impact factor: 5.157

6.  2'-Methoxy-6-methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA(A) receptors.

Authors:  Nasiara Karim; John Curmi; Navnath Gavande; Graham Ar Johnston; Jane R Hanrahan; M Louise Tierney; Mary Chebib
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

7.  Anxiolytic-like effects of mitragynine in the open-field and elevated plus-maze tests in rats.

Authors:  Ammar Imad Hazim; Surash Ramanathan; Suhanya Parthasarathy; Mustapha Muzaimi; Sharif Mahsufi Mansor
Journal:  J Physiol Sci       Date:  2014-01-25       Impact factor: 2.781

8.  Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at alpha1 plus alpha5 versus alpha2 plus alpha3 subunits account for dissimilarities in behavioral effects in rats?

Authors:  Miroslav M Savić; Samarpan Majumder; Shengming Huang; Rahul V Edwankar; Roman Furtmüller; Srdan Joksimović; Terry Clayton; Joachim Ramerstorfer; Marija M Milinković; Bryan L Roth; Werner Sieghart; James M Cook
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-01-13       Impact factor: 5.067

9.  Limiting activity at beta1-subunit-containing GABAA receptor subtypes reduces ataxia.

Authors:  Kelvin W Gee; Minhtam B Tran; Derk J Hogenkamp; Timothy B Johnstone; Rudy E Bagnera; Ryan F Yoshimura; Jin-Cheng Huang; James D Belluzzi; Edward R Whittemore
Journal:  J Pharmacol Exp Ther       Date:  2009-11-25       Impact factor: 4.030

10.  Contribution of alpha1 subunit-containing gamma-aminobutyric acidA (GABAA) receptors to motor-impairing effects of benzodiazepines in squirrel monkeys.

Authors:  Stephanie C Licata; Donna M Platt; James M Cook; Michael L Van Linn; James K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2008-11-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.